Oxurion NV's revenue for the
six
months ended in Dec. 2023 was €0.08 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.26 Mil.
Oxurion NV's Revenue per Share for the
six
months ended in Dec. 2023 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.
During the past 13 years, Oxurion NV's highest 3-Year average Revenue per Share Growth Rate was 146.40% per year. The lowest was -60.10% per year. And the median was -23.50% per year.
Oxurion NV Revenue Historical Data
The historical data trend for Oxurion NV's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oxurion NV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxurion NV's Revenue distribution charts can be found below:
* The bar in red indicates where Oxurion NV's Revenue falls into.
Oxurion NV Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxurion NV (XBRU:OXUR) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Oxurion NV Revenue Related Terms
Thank you for viewing the detailed overview of Oxurion NV's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBRU:OXUR has been successfully added to your 